Reading TWST? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TWST free→Reading TWST? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TWST free→QuarterlyIQ Insights · TWST
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 4, 2026, Twist Bioscience Corporation (the “ Company ”) issued a press release announcing its financial results for the quarter ended March 31, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Sect…
Other Events. Pursuant to Stock Purchase Agreements entered into with certain investors on February 11, 2026 (the “Stock Purchase Agreements”), Twist Bioscience Corporation (the “Company” or “Twist”) will issue up to an aggregate of 632,328 shares (the “Shares”) of its common stock, par value $0.00001 per share (the “Common Stock”). Of the Shares, the Company will issue up to 324,558 shares of Common Stock to Invenra Inc. (“Invenra”) and pay $5 million in cash in consideration for a license a…
Unregistered Sales of Equity Securities. The information set forth under
Results of Operations and Financial Condition. On February 2, 2026, Twist Bioscience Corporation (the “ Company ”) issued a press release announcing its financial results for the quarter ended December 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes…
Results of Operations and Financial Condition. On January 12, 2026, Twist Bioscience Corporation (the “ Company ”) issued a press release announcing its preliminary, unaudited revenue results for the first quarter ended December 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The Company’s revenue expectations included in this Current Report on Form 8-K are preliminary and unaudited and ar…
Results of Operations and Financial Condition. On November 14, 2025, Twist Bioscience Corporation (the “ Company ”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended September 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Trynka Shineman Blake to the Board of Directors On August 5, 2025, the Board of Directors (the “Board”) of Twist Bioscience Corporation (the “Company”) elected Trynka Shineman Blake to the Board, effective immediately. Ms. Shineman Blake will serve as a Class II director until her term expires at the Company’s 2026 Annual Meeting of…
Results of Operations and Financial Condition. On August 4, 2025, Twist Bioscience Corporation (the “ Company ”) issued a press release announcing its financial results for the quarter ended June 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Se…
Entry into a Material Definitive Agreement. On May 2, 2025, Twist Bioscience Corporation (“Twist”) entered into and closed on a Contribution Agreement (the “Contribution Agreement”) with Atlas Data Storage, Inc. (“Purchaser”), which secured approximately $155 million in investments, pursuant to which Purchaser acquired Twist’s DNA data storage product group, including certain intellectual property rights, equipment, contracts, and books and records related thereto (the “Contributed Assets”) a…
Regulation FD. In connection with the entry into the Contribution Agreement, License Agreement and MES Software License Agreement, Twist issued a press release, a copy of which is furnished as Exhibit 99.2 to this Current Report on Form 8-K. The information included in this Item 7.01, including Exhibit 99.2, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deeme…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain officers; Compensatory Arrangement of Certain Officers. As described in
Results of Operations and Financial Condition. On February 3, 2025, Twist Bioscience Corporation (the “ Company ”) issued a press release announcing its financial results for the quarter ended December 31, 2024. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes…
Importance-ranked changes since the prior daily snapshot.
Signal changed from 'mixed' to 'cautious'.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.